NasdaqCM - Delayed Quote • USD
ProQR Therapeutics N.V. (PRQR)
At close: 4:00 PM EDT
After hours: 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 6 | 5 |
| Avg. Estimate | -0.12 | -0.13 | -0.49 | -0.59 |
| Low Estimate | -0.17 | -0.19 | -0.72 | -0.95 |
| High Estimate | -0.07 | -0.06 | -0.31 | -0.29 |
| Year Ago EPS | -0.12 | -0.11 | -0.37 | -0.49 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 6 | 3 |
| Avg. Estimate | 3.36M | 3.36M | 17.11M | 25.12M |
| Low Estimate | -- | -- | -- | 8.58M |
| High Estimate | 5.46M | 5.46M | 29.32M | 45.37M |
| Year Ago Sales | 745.99k | 1.33M | 10.19M | 17.11M |
| Sales Growth (year/est) | 350.40% | 152.80% | 67.80% | 46.80% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.13 | -0.12 | -0.09 | 0.01 |
| EPS Actual | -0.12 | -0.11 | -0.08 | -0.07 |
| Difference | 0.01 | 0.01 | 0.01 | -0.08 |
| Surprise % | 7.70% | 8.30% | 11.10% | -800.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.12 | -0.13 | -0.49 | -0.59 |
| 7 Days Ago | -0.11 | -0.11 | -0.43 | -0.49 |
| 30 Days Ago | -0.11 | -0.12 | -0.44 | -0.5 |
| 60 Days Ago | -0.09 | -0.1 | -0.41 | -0.48 |
| 90 Days Ago | -0.09 | -0.1 | -0.41 | -0.48 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | 1 | 1 | 1 |
Growth Estimates
| CURRENCY IN USD | PRQR | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 0.00% | -- | -- | 2.60% |
| Next Qtr. | -18.20% | -- | -- | 13.40% |
| Current Year | -32.40% | -- | -- | 5.20% |
| Next Year | -20.40% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.11% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Citigroup: Neutral to Neutral | 4/18/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/14/2024 |
| Maintains | Chardan Capital: Buy to Buy | 3/14/2024 |
| Maintains | Raymond James: Outperform to Outperform | 11/8/2023 |
| Upgrade | Chardan Capital: Neutral to Buy | 11/8/2023 |
| Maintains | Citigroup: Buy to Buy | 9/18/2023 |
Related Tickers
ARWR Arrowhead Pharmaceuticals, Inc.
21.87
-6.10%
WVE Wave Life Sciences Ltd.
4.7400
-5.39%
AFMD Affimed N.V.
4.8800
0.00%
IPSC Century Therapeutics, Inc.
3.1500
+6.42%
LBPH Longboard Pharmaceuticals, Inc.
19.25
-2.53%
LPTX Leap Therapeutics, Inc.
3.1700
-3.65%
SGMO Sangamo Therapeutics, Inc.
0.5030
+2.03%
LVTX LAVA Therapeutics N.V.
2.6400
-3.65%
SLN Silence Therapeutics plc
21.62
-2.92%
MDNAF Medicenna Therapeutics Corp.
1.4000
+0.72%